Scarica l'app Stockscreener
9.19
0.88%
0.08
Dopo l'orario di chiusura:
9.25
0.06
+0.65%
Precedente Chiudi:
$9.11
Aprire:
$8.9
Volume 24 ore:
6.12M
Relative Volume:
1.29
Capitalizzazione di mercato:
$2.19B
Reddito:
$510.17M
Utile/perdita netta:
$146.93M
Rapporto P/E:
15.34
EPS:
0.599
Flusso di cassa netto:
$27.51M
1 W Prestazione:
+10.86%
1M Prestazione:
-44.57%
6M Prestazione:
-36.75%
1 anno Prestazione:
-54.57%
Intervallo 1D:
$8.80
$9.255
Intervallo di 1 settimana:
$8.80
$9.805
Portata 52W:
$7.2101
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.19 | 2.19B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA SEC FilingsAdma Biologics 10-K, 10-Q, 8-K Forms - Stock Titan
ADMA PE Ratio & Valuation, Is ADMA Overvalued - intellectia.ai
US High Growth Tech Stocks To Watch For Potential Expansion - Sahm
Stock Drop Alert: ADMA Biologics ($ADMA) Stock Plummets 29% after Channel Stuffing Claims DisclosedInvestors Notified of Securities Fraud Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Investors to Connect - ACCESS Newswire
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc. - ACCESS Newswire
ADMA (ADMA) COO reports 20,362-share RSU tax withholding, holds 446,238 shares - Stock Titan
ADMA Biologics gains after refuting short seller claims - MSN
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Investors to Connect | NDAQ:ADMA | Press Release - Stockhouse
ADMA Biologics Investigated for Securities Fraud After Plunge - National Today
Bronstein, Gewirtz & Grossman, LLC Encourages ADMA Biologics, Inc. (ADMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
$ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA Law - GlobeNewswire Inc.
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Trading the Move, Not the Narrative: (ADMA) Edition - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADMA Biologics, Inc. (ADMA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ADMA Investor Alert: ADMA Biologics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky - Sahm
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqui - The National Law Review
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation – ADMA - Eagle-Tribune
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026? - Zacks Investment Research
ADMA Biologics Under Investigation for Securities Fraud - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Investors to Reach Out - ACCESS Newswire
Investor Notice: ADMA Biologics ($ADMA) Stock Dropped 29% After Culper Research Report AnnouncementInvestigation Pending - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA ... - Bluefield Daily Telegraph
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ... - Bluefield Daily Telegraph
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
ADMA Biologics Investigated for Securities Fraud After Stock Drop - National Today
ADMA Biologics Investigated for Securities Fraud After Plummeting Stock - National Today
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop - PR Newswire
Adma Biologics (ADMA) Shares Fall as Overall Market Rises: Key Insights for Investors - Bitget
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - PR Newswire
2026-03-30 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out | NDAQ:ADMA | Press Release - Stockhouse
$ADMA Investor News: ADMA Biologics Faces Securities Fraud - globenewswire.com
ADMA Biologics (ADMA) soars 11.6% as firm denies short seller allegations - MSN
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
ADMA’s Upward Candlesticks Face Off Against a 41.6% Price Decline — What Lies Ahead? - Bitget
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect - ACCESS Newswire
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect | NDAQ:ADMA | Press Release - Stockhouse
Did ADMA Biologics($ADMA) Mislead Investors about Channel Stuffing Issues? Investors with Losses Notified of Ongoing Securities Fraud Investigation - ACCESS Newswire
ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade) - Seeking Alpha
ADMA Biologics Faces Increased Short Interest Amid Allegations - National Today
ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update - marketbeat.com
Does ADMA Biologics’ (ADMA) Rebuttal to Short-Seller Claims Strengthen Its Management Credibility Narrative? - Yahoo Finance
ADMA stock drops 6% after Culper Research alleges channel stuffing - msn.com
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
Is ADMA Biologics' (ADMA) Rebuttal of Short-Seller Claims a Crucial Test of Management Credibility? - Sahm
5 Stocks Investors Are Tracking Now - Insider Monkey
ADMA Biologics (ADMA) Soars 11.6% as Firm Denies Short Seller Allegations - finance.yahoo.com
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adma Biologics Inc Azioni (ADMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):